Behavioural brain research · 2026
Xiaochaihu decoction alleviates chronic stress-induced depressive-like behavior in mice by modulating the gut microbiota-brain axis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Xiangwei, Liang Jing, Zhou Ting, Hou Jun, Yu Jingzi, Shi Jinfu, Du Jun, Wang Haitao, Zhang Xiujun, Shang Xueliang
Аннотация
BACKGROUND: Xiaochaihu Decoction (XCHD) has shown potential in treating neurological disorders, but its mechanisms in alleviating depression remain unclear.
AIM OF THE STUDY: The aim of this study was to examine if the XCHD was able to alleviate depressive-like impairment in a mouse model of chronic mild stress.
MATERIALS AND METHODS: Fifty male C57BL/6 mice were divided into five groups: control (CON), stress (CUMS), stress with low and high XCHD doses (CUMS+L-XCHD, CUMS+H-XCHD), and fluoxetine (CUMS+FLX). The deprssion model was established using chronic unpredictable mild stress (CUMS) and isolated feeding. Animal behavior was assessed using the sucrose preference and open-field tests. Neuroplasticity, inflammation, and gut microbiota were analyzed using Western blotting, immunofluorescence, and 16S rRNA sequencing.
RESULTS: XCHD increased sucrose consumption and improved spatial learning and memory in stressed mice. It also alleviated anxiety and behavioral despair, restored hippocampal neuroplasticity, and reduced inflammation. XCHD modulated the Nogo-A/S1P2R-Gαq-PKC signaling pathway and enhanced tight junction proteins in the colon. Additionally, XCHD restored gut microbiota balance, increasing Firmicutes and reducing Bacteroides and Proteobacteria.
CONCLUSION: XCHD ameliorates depressive-like symptoms by modulating the gut microbiota-brain axis, enhancing neuroplasticity, and reducing inflammation, suggesting its potential as an antidepressant therapy.
AIM OF THE STUDY: The aim of this study was to examine if the XCHD was able to alleviate depressive-like impairment in a mouse model of chronic mild stress.
MATERIALS AND METHODS: Fifty male C57BL/6 mice were divided into five groups: control (CON), stress (CUMS), stress with low and high XCHD doses (CUMS+L-XCHD, CUMS+H-XCHD), and fluoxetine (CUMS+FLX). The deprssion model was established using chronic unpredictable mild stress (CUMS) and isolated feeding. Animal behavior was assessed using the sucrose preference and open-field tests. Neuroplasticity, inflammation, and gut microbiota were analyzed using Western blotting, immunofluorescence, and 16S rRNA sequencing.
RESULTS: XCHD increased sucrose consumption and improved spatial learning and memory in stressed mice. It also alleviated anxiety and behavioral despair, restored hippocampal neuroplasticity, and reduced inflammation. XCHD modulated the Nogo-A/S1P2R-Gαq-PKC signaling pathway and enhanced tight junction proteins in the colon. Additionally, XCHD restored gut microbiota balance, increasing Firmicutes and reducing Bacteroides and Proteobacteria.
CONCLUSION: XCHD ameliorates depressive-like symptoms by modulating the gut microbiota-brain axis, enhancing neuroplasticity, and reducing inflammation, suggesting its potential as an antidepressant therapy.